as of 12-05-2025 3:46pm EST
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 864.4M | IPO Year: | N/A |
| Target Price: | $11.64 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.97 - $23.97 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,759,900,000 | Revenue Growth: | 1.88% |
| Revenue Growth (this year): | 3.17% | Revenue Growth (next year): | 0.04% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Accounting Officer
Avg Cost/Share
$9.95
Shares
7,338
Total Value
$73,013.10
Owned After
19,046
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$10.23
Shares
3,156
Total Value
$32,285.88
Owned After
58,770
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$10.23
Shares
3,155
Total Value
$32,275.65
Owned After
56,976
SEC Form 4
General Counsel
Avg Cost/Share
$10.23
Shares
1,677
Total Value
$17,155.71
Owned After
19,092
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$10.23
Shares
592
Total Value
$6,056.16
Owned After
19,046
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Parks Robert | FTRE | Chief Accounting Officer | Sep 16, 2025 | Sell | $9.95 | 7,338 | $73,013.10 | 19,046 | |
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Sep 9, 2025 | Sell | $10.23 | 3,156 | $32,285.88 | 58,770 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Sep 9, 2025 | Sell | $10.23 | 3,155 | $32,275.65 | 56,976 | |
| Hanson James S. | FTRE | General Counsel | Sep 9, 2025 | Sell | $10.23 | 1,677 | $17,155.71 | 19,092 | |
| Parks Robert | FTRE | Chief Accounting Officer | Sep 9, 2025 | Sell | $10.23 | 592 | $6,056.16 | 19,046 |
See how FTRE stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "FTRE Fortrea Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.